SBBP - Strongbridge Bio guides Q4 and FY20 revenue above consensus shares up 3%

Strongbridge Biopharma (SBBP) sees Q4 Keveyis (dichlorphenamide) net product sales of ~$8.2M, consensus of $7.05M.FY 2020 Keveyis revenue is expected to be ~$30.7M, exceeding projections of $28M - $29M, and well ahead of consensus $29.44M.FY 2021 Keveyis revenue outlook of ~$34M to $36M. Strongbridge is on-track to submit a NDA for Recorlev to the FDA in Q1 2021; if approved, the launch is anticipated in Q1 2022.The company expects to report ~$87.5M of cash and equivalents as of December 31, 2020. SBBP believes it can fund operations into and potentially beyond Q1 2023.Shares up 3% premarket.

For further details see:

Strongbridge Bio guides Q4 and FY20 revenue above consensus, shares up 3%